CARDIOVASCULAR JOURNAL OF AFRICA • Volume 35, No 1, January – April 2024 26 AFRICA impact on prognosis. Curr Cardiol Rep 2013; 15(3). 57. Chillo P, Mashili F, Kwesigabo G, Ruggajo P, Kamuhabwa A. Developing a sustainable cardiovascular disease research strategy in Tanzania through training: leveraging from the East African Centre of Excellence in Cardiovascular Sciences Project. Front Cardiovasc Med 2022; 9(March): 1–11. 58. Longenecke CT, Kalra A, Emmy Okello, Lwabi P, Omagino JO, Kityo C, et al. A human-centered approach to CV care: infrastructure development in Uganda. Glob Heart 2018; 13(4): 347–354. 59. Faletra FF, Nucifora G, Ho SY. Imaging the atrial septum using realtime three-dimensional transesophageal echocardiography: Technical tips, normal anatomy, and its role in transseptal puncture. J Am Soc Echocardiogr 2011; 24(6): 593–599. 60. Valocik G, Kamp O, Visser CA. Three-dimensional echocardiography in mitral valve disease. Eur J Echocardiogr 2005; 6(6): 443–454. 61. Eighth Tokyo International Conference on African Development (TICAD 8) Tunis Declaration. (August 2022): 1–11. Available from: https://www.mofa.go.jp 62. Beaton A, Okello E, Lwabi P, Mondo C, McCarter R, Sable C. Echocardiography screening for rheumatic heart disease in ugandan schoolchildren. Circulation 2012; 125(25): 3127–3132. 63. Yadeta D, Hailu A, Haileamlak A, Gedlu E, Guteta S, Tefera E, et al. Prevalence of rheumatic heart disease among school children in Ethiopia: A multisite echocardiography-based screening. Int J Cardiol 2016; 221: 260–263. 64. Engel ME, Haileamlak A, Zühlke L, Lemmer CE, Nkepu S, Van De Wall M, et al. Prevalence of rheumatic heart disease in 4720 asymptomatic scholars from South Africa and Ethiopia. Heart 2015; 101(17): 1389–1394. 65. Mutagaywa RK, Kamuhabwa A, Wind A, Cramer MJ, Chillo P, Chamuleau S. Rheumatic heart disease anno 2020: Impacts of gender and migration on epidemiology and management. Eur J Clin Invest 2020; 50(12): e13374. 66. Kazahura PT, Mushi TL, Pallangyo P, Janabi M, Kisenge R, Albaghdadi M, et al. Prevalence and risk factors for subclinical rheumatic heart disease among primary school children in Dar es Salaam, Tanzania: a community based cross-sectional study. BMC Cardiovasc Disord 2021; 21(1): 1–14. 67. Marijon E, Ou P, Celermajer DS, Ferreira B, Mocumbi AO, Jani D, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med 2007; 357(5): 470–476. 68. Mutagaywa RK, Vroon JC, Fundikira L, Wind AM, Kunambi P, Joel M, et al. Infective endocarditis in developing countries: An update. Front Cardiovasc Med 2022. 69. Mutagaywa RK, Kamala BA, Cramer M, Chamuleu S, Chillo P, Tumaini B, et al. Predictors of early mortality following cardiac surgery for rheumatic heart disease at a national referral hospital in Dar es Salaam, Tanzania: A retrospective study. East Cent African J Surg 2022. 70. Mutagaywa RK, Mwakigonja A, Chillo P, Ngaiza A, Byomuganyizi M, Fundikira L, et al. Histopathological evaluation of chronic rheumatic mitral valve stenosis: the association with clinical presentation, pathogenesis, and management at a National Cardiac Institute, Tanzania. Cardiovasc Pathol 2022; 60: 107434. 71. Riaz BK, Selim S, Karim MN, Chowdhury KN, Chowdhury SH, Rahman MR. Risk factors of rheumatic heart disease in bangladesh: A case-control study. J Heal Popul Nutr 2013; 31(1): 70–77. 72. Negi PC, Kandoria A, Asotra S, Ganju N kumar, Merwaha R, Sharma R, et al. Gender differences in the epidemiology of rheumatic fever/ rheumatic heart disease (RF/RHD) patient population of hill state of northern India; 9 years prospective hospital based, HP-RHD registry. Indian Heart J 2020; 72(6): 552–556. 73. Passos LSA, Nunes MCP, Aikawa E. Rheumatic heart valve disease pathophysiology and underlying mechanisms. Front Cardiovasc Med 2021; 7(January): 1–10. 74. Passos LSA, Jha PK, Becker-Greene D, Blaser MC, Romero D, Lupieri A, et al. Prothymosin alpha: a novel contributor to estradiol receptor alpha–mediated CD8 + T-cell pathogenic responses and recognition of type 1 collagen in rheumatic heart valve disease. Circulation 2022; 145(7): 531–548. 75. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392(10159): 1859–1922. 76. Beaton A, Okello E, Rwebembera J, Grobler A, Engelman D, Alepere J, et al. Secondary antibiotic prophylaxis for latent rheumatic heart disease. N Engl J Med 2022; 386(3): 230–240. 77. Diao M, Kane A, Ndiaye MB, Mbaye A, Bodian M, Dia MM, et al. Pregnancy in women with heart disease in sub-Saharan Africa. Arch Cardiovasc Dis 2011; 104(6–7): 370–374. 78. Van Hagen IM, Thorne SA, Taha N, Youssef G, Elnagar A, Gabriel H, et al. Pregnancy outcomes in women with rheumatic mitral valve disease: results from the registry of pregnancy and cardiac disease. Circulation 2018; 137(8): 806–816. 79. Sliwa K, Libhaber E, Elliott C, Momberg Z, Osman A, Zühlke L, et al. Spectrum of cardiac disease in maternity in a low-resource cohort in South Africa. Heart 2014; 100(24): 1967–1974. 80. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J 2011; 32(24): 3147–3197.
RkJQdWJsaXNoZXIy NDIzNzc=